Logo

PTPI

Petros Pharmaceuticals, Inc.

PTPI

Petros Pharmaceuticals, Inc. • NASDAQ
$0.01 ▲ 0.00% (+0.00)
Market Cap $373921
52w High $16.25
52w Low $0.01
Dividend Yield 0%
P/E 0
Volume 66.65K
Outstanding Shares 31.16M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $990.737K ▼ $-922.723K ▼ 0% $-0.022 ▲ $-214.918K ▲
Q2-2025 $0 $1.801M ▲ $5.433M ▲ 0% $-1.29 ▲ $-1.801M ▼
Q1-2025 $0 ▼ $1.458M ▼ $-2.26M ▲ 0% ▲ $-9.37 ▼ $-1.458M ▲
Q4-2024 $725.403K ▼ $9.591M ▲ $-9.273M ▼ -1.278K% ▼ $-0.13 ▲ $-8.439M ▼
Q3-2024 $1.576M $3.629M $-2.221M -140.872% $-1.15 $-1.294M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $6.07M ▼ $6.133M ▼ $2.765M ▼ $3.368M ▼
Q2-2025 $7.322M ▼ $7.397M ▼ $2.95M ▼ $4.447M ▲
Q1-2025 $8.931M ▲ $17.605M ▲ $27.19M ▲ $-9.584M ▼
Q4-2024 $3.71M ▼ $10.635M ▼ $18.103M ▲ $-7.468M ▼
Q3-2024 $3.895M $20.694M $17.577M $3.117M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-922.723K ▼ $-1.134M ▲ $0 $-117.311K ▲ $-1.251M ▲ $-1.134M ▲
Q2-2025 $4.932M ▲ $-3.007M ▼ $0 $-428.233K ▼ $-3.435M ▼ $-3.007M ▼
Q1-2025 $-1.2M ▲ $-1.66M ▼ $0 ▲ $8.707M ▲ $7.047M ▲ $-1.66M ▼
Q4-2024 $-9.273M ▼ $965.405K ▲ $-5.449K ▲ $-1.145M ▲ $-184.714K ▲ $959.956K ▲
Q3-2024 $-2.221M $-771.246K $-19.138K $-2.775M $-3.565M $-790.384K

Revenue by Products

Product Q1-2024Q2-2024Q3-2024Q4-2024
Medical Devices
Medical Devices
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement The income statement shows a company that is still in a very early commercial stage. Revenue has been minimal and essentially flat for several years, which means the business is not yet generating meaningful sales from its products or platform. Gross profit is close to zero, suggesting limited product volume and little room to absorb fixed costs. Operating losses have been steady, reflecting ongoing spending on development, overhead, and commercialization efforts without a matching rise in revenue. Net losses are recurring, and the very large swings in per‑share figures mainly reflect reverse stock splits rather than fundamental change. Overall, the story here is of a development‑focused company that has not yet converted its strategy into meaningful top‑line growth or profitability.

Balance Sheet

Balance Sheet The balance sheet is small and has weakened over time. Total assets and cash have trended down from earlier years, indicating that prior funding is being used to cover operations. Debt is present, and equity has recently turned negative, meaning liabilities now exceed assets. That kind of capital structure often signals financial strain and a heavy reliance on external financing to stay on track. There is little balance‑sheet cushion if results or funding conditions worsen, so the company’s financial flexibility appears limited.

Cash Flow

Cash Flow Cash flow patterns are typical of a development‑stage healthcare company: money flows out, not in. Operating cash flow has been negative in most years, showing that day‑to‑day activities consume cash rather than generate it. Since capital spending is negligible, free cash flow largely mirrors operating cash flow. In practical terms, this means progress on the business plan is being funded by prior cash balances and, likely, periodic capital raises rather than by the business itself. Sustaining the strategy will depend on continued access to new funding or a future shift toward stronger revenue and margins.

Competitive Edge

Competitive Edge Competitively, Petros is a very small player operating in large, crowded markets. Its legacy focus is men’s health, anchored by an erectile dysfunction drug, where it faces major, well‑funded competitors and widely available alternatives. The newer focus—using technology to help other companies move drugs from prescription to over‑the‑counter status—is more niche and less crowded, which creates an opening for differentiation. The company’s potential edge comes from regulatory know‑how and a purpose‑built technology platform rather than sheer scale. However, its small size, limited financial resources, and dependence on regulatory outcomes and partnerships leave it vulnerable to delays, larger rivals, and shifting FDA expectations.

Innovation and R&D

Innovation and R&D Innovation is the core of the Petros story. The company is trying to move beyond being a single‑product men’s health business into a tech‑enabled services model built around Rx‑to‑OTC transitions. The planned SaaS and software‑as‑a‑medical‑device platform uses AI, big data, and EHR integration to help screen and guide consumers safely—aligned with the FDA’s newer framework for nonprescription drugs with added conditions. Early study results on user comprehension are encouraging, and STENDRA serves as both a commercial asset and a live test case for the platform. Still, much of this remains in development: real‑world adoption, partner uptake, regulatory approvals, and revenue contribution are all future‑oriented and uncertain. R&D and regulatory work are likely absorbing a meaningful share of resources without yet delivering broad commercial proof.

Summary

Overall, Petros Pharmaceuticals looks like a high‑risk, early‑stage transition story. Financially, it has very small, flat revenue, consistent operating and net losses, a thin and recently negative equity base, and ongoing cash burn—signs of a company still far from self‑funding operations. Strategically, it is trying to pivot from a small men’s health drug business into a specialized technology and regulatory partner for Rx‑to‑OTC switches, with a potential first‑mover angle in a growing self‑care market. The main opportunities lie in successfully commercializing its platform, securing partnerships, and advancing STENDRA or other products into OTC channels. The main risks center on execution, regulatory outcomes, competitive response, and the need for continued external capital. This makes the story highly dependent on future milestones rather than current financial strength.